MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

Raoul A. Droeser1,2†, Robert Mechera1†, Silvio Däster1, Benjamin Weixler1, Marko Kraljević1, Tarik Delko1, Uwe Güth3,4, Sylvia Stadlmann5,6, Luigi Terracciano6 and Gad Singer5,6

Abstract

Background: Cancer of the ovary is mostly discovered at a late stage and cannot be removed by surgery alone. Therefore surgery is usually followed by adjuvant chemotherapy. However, few reliable biomarkers exist to predict response to chemotherapy of ovarian cancer. Previously, we could demonstrate that IL-17 density is indicative for chemosensitivity. This study focuses on the predictive value of myeloperoxidase (MPO) concerning response to chemotherapy of ovarian cancer.

Methods: Biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were stained with MPO after fixation in formalin and embedding in paraffin. For this staining the technique of tissue-microarray was used. Recurrence within 6 months of the completion of platinum-based chemotherapy was defined as chemoresistance as previously published. Data for MPO could be analyzed in 92 biopsies.

Results: MPO and IL-17 positive immune cells correlated significantly in biopsies of primary and recurrent carcinomas (rs = 0.41; p = 0.004 and rs = 0.40; p = 0.007, respectively). MPO expression alone did not predict response to chemotherapy, but in multivariate cox regression analysis including age, residual disease, number of chemotherapy cycles, FIGO classification and combined categorized MPO and IL-17 cell densities of primary cancer biopsies, the combination of both immune markers was an independent prognostic factor for recurrence-free survival (p = 0.013, HR = 0.23, 95CI = 0.07–0.73). There was no chemoresistant patient in the subgroup of MPO + IL-17+, neither in primary nor in recurrent cancer biopsies.

Conclusions: High MPO positive cell density enhances the indicative value of IL-17 for response to chemotherapy in ovarian carcinoma. Although, these results have to be validated in a larger cohort.

Keywords: Myeloperoxidase, Interleukin-17, Synergistic effect, Ovarian cancer, Chemosensitivity

Abbreviations: IL-17, Interleukin-17; MPO, Myeloperoxidase; TMA, Tissue microarray

Background

Ovarian cancer has an incidence range of 5-15/100'000 in Europe [1–3]. It is only the 5th most common female cancer, but even though it is the most lethal of all female genital carcinomas. It is mostly discovered at a late stage and cannot be removed by surgery alone due to late and unspecific symptoms. Surgical debulking is usually followed by adjuvant platinum-based chemotherapy. However, most patients recur with chemoresistant disease.

It is known that tumor microenvironment influences tumor biology and that tumor behavior is affected by the immunological environment. According to several previous publications tumor microenvironment seems to have significant impact on survival and tumor growth [4–8]. Tumor-infiltrating lymphocytes (TILs) are frequently thought to mirror tumor immune response to invasive neoplasms [9]. They were discovered in different solid tumors [10, 11]. Indeed, in colorectal cancer
(CRC) the “immune contexture” [12], especially cells of the adaptive immune response, are more important concerning prognosis than the TNM staging and might help in decision making for personalized treatment [13, 14]. There are several previous studies that analyzed different markers predicting response to platinum-based chemotherapy in ovarian cancer with the scope to optimize adjuvant treatment [15–17]. However, only few markers were helpful.

On one side it is known that FOXP3 positive regulatory T (Treg) cell infiltration is associated with decreased survival in ovarian cancer [17–19]. On the other side, granulocytes have largely been neglected by tumor immunologists [20]. Challenging this, recent studies implied that neutrophil granulocytes might play an important role in the prevention of cancer metastasis [21]. Finally, neutrophil granulocytes are thought to have the capacity to undergo differentiation into N1 and N2 cells with anti- and pro-tumor properties, respectively [22, 23]. Therefore tumor infiltrating granulocytes regain attention in research [24–26].

In a previous study we could demonstrate that IL-17, but not FOXP3 positive immune cell infiltration in primary and recurrent ovarian carcinoma were indicative of chemosensitivity [27]. Finally it has been shown that IL-17 can be produced by granulocytes [28, 29] and other innate immune cells [30] and not only by TILs. However, in ovarian cancer the role of the innate immune system has not been evaluated to the same extent as the role of the adaptive immune system. In early stage lung cancer granulocytes have recently been shown to stimulate T cell responses in humans [31].

Neutrophilic granulocytes (NG) accumulate myeloperoxidase (MPO) in high amounts during their early maturation phase [32]. MPO produces hypochlorous acid from hydrogen peroxide and chloride anion and is responsible for the oxidization of tyrosine to tyrosyl radicals. Both are cytotoxic to a variety of microorganisms. After activation of granulocytes this enzyme is also implicated in the induction of apoptosis [33, 34].

There are few studies reporting the prognostic and predictive role of MPO in ovarian cancer. Therefore, we investigated its predictive value for chemosensitivity alone and in combination with IL-17 expression in a well characterized cohort of primary ovarian carcinomas and their matched recurrences which has also been used for previous publications of our group [35–38].

Mostly high-grade ovarian carcinomas (5.7 % FIGO stage II, 84.3 % FIGO stage III and 4.3 % FIGO stage IV) were included in this study after typing according to previous publications [39, 40]. The tissue microarray (TMA) was available from previous studies [35–38]. All patients had recurrences after initial surgery and had received at least three cycles of platinum-based adjuvant chemotherapy. The collection was divided into two groups according to response to chemotherapy. Recurrence occurring within 6 months after completion of platinum-based chemotherapy was defined as resistance [41]. The TMA allows investigation of tissues from ovarian carcinomas and matched recurrences from the same patients as previously shown [35–38]. The statement concerning the clinical data collection and ethical considerations can be found in previous publications [27, 35–38].

### Tissue microarray construction

The construction of the tissue microarray has been previously described [27, 42].

### Immunohistochemistry (IHC) and visual analysis

Standard indirect immunoperoxidase procedures (ABC-Elite, Vectra Laboratories) were used for immunohistochemistry. For MPO staining the following antibody was used: clone 59A5 Novocastra, Newcastle, UK. In each tissue spot positive stained tumor immune cell infiltration (TICI) in the stroma was counted, representing approximately one high-power-field (10×), intravascular cells were excluded from analysis (Fig. 1a and b). Two independent experienced observers (RM and GS) analyzed the staining for specificity and the amount of TICI as described above. Cut-off was 22 positive cells/punch for MPO. Conclusive data for MPO were available in 47 biopsies of primary and 45 biopsies of matched recurrent carcinomas, respectively.

### Statistical analysis section

Cut-off scores used to classify ovarian carcinomas with low or high MPO infiltration were obtained by regression tree analysis, evaluating the best threshold in order to predict patients’ survival status, on all tumor samples [43]. Specific scores were set at 22 positive cells/punch. IL-17 data were available from a previous publication [27]. Kruskal Wallis, Chi-Square or Fisher’s Exact tests were used for the association of the clinicopathological features with the corresponding four groups of the biomarkers. Univariate recurrence-free and overall survival analysis was carried out by the Kaplan-Meier method and log rank test.

The assumption of proportional hazards was verified for both markers by analyzing the correlation of Schoenfeld residuals and the ranks of individual failure times. Any missing clinicopathological information was assumed to be missing at random. Subsequently, a multivariate Cox
regression analysis was performed including MPO and IL-17. The hazard ratios (HR) and the 95 % confidence intervals (CI) were used to determine prognostic effects on survival time. Spearman’s rank correlation was used to analyze the correlation between MPO and IL-17. All statistical analyses were made using STATA software version 13 (StataCorp, College Station, TX, USA).

Results
Patient characteristics
The baseline characteristics of the patient cohort have been described previously [27] (Table 1). Briefly recurrence-free (RFS) and overall survival (OS) in the chemoresistant

### Table 1 Patient characteristics ($n = 47$)

|                  | MPO high       | MPO low        | p-value |
|------------------|----------------|----------------|---------|
| Age (median, range) | 55 (45–73)     | 60 (34–77)     | 0.196   |
| FIGO stage       |                |                |         |
| II               | 0              | 1 (2.9)        | 0.401   |
| IIIA             | 0              | 1 (2.9)        |         |
| III              | 3 (25.0)       | 2 (5.7)        |         |
| IIIC             | 7 (58.3)       | 25 (71.4)      |         |
| IV               | 2 (16.7)       | 6 (17.1)       |         |
| Residual disease |                |                |         |
| None             | 4 (33.3)       | 12 (34.3)      | 0.919   |
| <2 cm            | 5 (41.7)       | 12 (34.3)      |         |
| >2 cm            | 3 (25.0)       | 10 (28.6)      |         |
| Numbers of chemotherapy cycles |               |                |         |
| <6               | 1 (8.3)        | 6 (17.1)       | 0.440   |
| 6 or more        | 11 (91.7)      | 28 (80.0)      |         |
| Primary cancer biopsies |            |                |         |
| CS$^b$           | 10 (83.3)      | 23 (65.7)      | 0.249   |
| CR$^b$           | 2 (16.7)       | 12 (34.3)      |         |
| Recurrent cancer biopsies ($n = 10/35$) |        |                |         |
| CS$^b$           | 9 (90.0)       | 23 (65.7)      | 0.135   |
| CR$^b$           | 1 (10.0)       | 12 (34.3)      |         |
| RFS$^c$ (mean/SE) | 11.9 (2.7)     | 9.5 (1.6)      | 0.380   |
| OS$^c$ (mean/SE) | 56.8 (14.4)    | 39.3 (4.4)     | 0.139   |

### Table 2 Patients’ characteristics according to dichotomized distribution of MPO in the overall cohort ($n = 47$)

*missing clinicopathological information was assumed to be missing at random

$^a$CS chemosensitive, CR chemoresistant

$^b$RFS recurrence-free survival, OS overall survival

**Fig. 1** MPO and corresponding IL-17 specific staining in high grade ovarian carcinoma. Tumor punches are representative of low (panel a) and high (panel b) density of MPO positive TICI. Panel c shows an IL-17 specific staining in a section from the same biopsy shown in b. Magnification: 10x
Fig. 2 a Kaplan Meier survival curve of recurrence-free survival according to MPO and IL-17 density in primary cancer biopsies. Impact of MPO+ and IL-17+ tumor infiltrating immune cells on recurrence-free survival in patients with high grade ovarian carcinoma. Kaplan-Meier recurrence-free survival curves were split according to MPO+ and IL-17+ cell density in patients bearing high grade ovarian carcinoma as indicated. Cut-off values established by regression tree analysis were 22 cells/punch for MPO and 1 cell/punch for IL-17 cell infiltration. Cumulative effects of tumor infiltration by MPO+ and IL-17+ cells were explored. Blue line indicates to tumors with low MPO+ and low IL-17+ cell infiltration. Green line refers to tumors with high IL-17+ cell infiltration. Red line refers to tumors with high MPO+ cell infiltration and yellow line refers to tumors with high MPO+ and high IL-17+ cell infiltration.

b Kaplan Meier survival curve of overall survival according to MPO and IL-17 density in primary cancer biopsies. Impact of MPO+ and IL-17+ tumor infiltrating immune cells on overall survival in patients with high grade ovarian carcinoma. Kaplan-Meier overall survival curves were split according to MPO+ and IL-17+ cell density in patients bearing high grade ovarian carcinoma as indicated. Cut-off values established by regression tree analysis were 22 cells/punch for MPO and 1 cell/punch for IL-17 cell infiltration. Cumulative effects of tumor infiltration by MPO+ and IL-17+ cells were explored. Blue line indicates to tumors with low MPO+ and low IL-17+ cell infiltration. Green line refers to tumors with high IL-17+ cell infiltration. Red line refers to tumors with high MPO+ cell infiltration and yellow line refers to tumors with high MPO+ and high IL-17+ cell infiltration.

Table 3 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in primary carcinomas (n = 47) a

| Variable                  | MPO-/IL17- | MPO+/IL17- | MPO-/IL17+ | MPO+/IL17+ | p-value |
|---------------------------|------------|------------|------------|------------|---------|
| Age (median, range)       | 62 (39–77) | 59.5 (50–65)| 57 (34–72) | 55 (45–73) | 0.742   |
| FIGO stage                |            |            |            |            |         |
| II                        | 0          | 0          | 1 (8.3)    | 0          | 0.029   |
| IIIA                      | 1 (4.7)    | 0          | 0          | 0          |         |
| IIIB                      | 2 (9.5)    | 0          | 0          | 3 (50.0)   |         |
| IIIC                      | 17 (81.1)  | 5 (62.5)   | 8 (66.7)   | 2 (33.3)   |         |
| IV                        | 1 (4.7)    | 3 (37.5)   | 3 (25.0)   | 1 (16.7)   |         |
| Residual disease          |            |            |            |            |         |
| None                      | 9 (42.9)   | 2 (25.0)   | 3 (25.0)   | 2 (33.3)   | 0.262   |
| <2 cm                     | 6 (28.6)   | 1 (12.5)   | 7 (58.3)   | 3 (50.0)   |         |
| >2 cm                     | 5 (23.8)   | 5 (62.5)   | 2 (16.7)   | 1 (16.7)   |         |
| Numbers of chemotherapy cycles |        |            |            |            |         |
| <6                        | 5 (23.8)   | 0          | 1 (8.3)    | 1 (16.7)   | 0.412   |
| 6 or more                 | 15 (71.4)  | 8 (100.0)  | 11 (91.7)  | 5 (83.3)   |         |
| CSB                       | 14 (66.7)  | 2 (25.0)   | 11 (91.7)  | 6 (100.0)  | 0.004   |
| CRe                       | 7 (33.3)   | 6 (75.0)   | 1 (8.3)    | 0          |         |
| RFS (mean/SE)             | 8.1 (1.7)  | 3.9 (1.6)  | 14.9 (3.3) | 16 (3.9)   | 0.024   |
| OS (mean/SE)              | 36 (4.5)   | 33.4 (9.6) | 52.4 (12.1)| 72 (15.0)  | 0.113   |

Bold data statistically significant p < 0.05

apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random.

Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher's Exact test

bCS chemosensitive, CR chemoresistant

cRFS recurrence-free survival, OS overall survival
group was significantly shorter than in the chemosensitive group (2.2 ± 0.3 vs 18.2 ± 2.0 months, p < 0.0001 and 27 ± 5.3 vs. 49.6 ± 4.0 months, p = 0.0003, respectively). The analysis by MPO density is summarized in Table 2.

MPO positive immune cell infiltration in paired primary and recurrent ovarian carcinoma
Mean number of infiltrating MPO positive cells in primary and recurrent cancer biopsies were 16.6 (±21.6) and 19.0 (±34.8), respectively. Neither for dichotomized MPO density in primary, nor in recurrent cancer biopsies a significant association with any clinicopathological feature was found (Table 2). Twelve out of 47 and 10 out of 45 displayed a high MPO cell density in primary and recurrent cancer biopsies, respectively. Finally, MPO density in primary and recurrent cancer biopsies did not show any significant association with chemosensitivity (p = 0.249 and p = 0.135) or any other clinicopathological feature (Table 2).

Correlation analysis of MPO and IL-17 positive tumor immune cell infiltration
For more information concerning the relationship of MPO and IL-17 positive cell infiltration a correlation analysis of both markers was performed. Interestingly MPO and IL-17 positive TICI correlated significantly in all biopsies (r_s = 0.42; p < 0.001), in biopsies of only primary (r_s = 0.41; p = 0.004) and in biopsies of only recurrent carcinomas (r_s = 0.40; p = 0.007).

Combined analysis of MPO and IL-17 positive cell density
Based on the correlation analysis results, a combined analysis of MPO and IL-17 cell density was performed. As shown in Fig. 2a, MPO and IL-17 positive TICI frequency was significantly associated with a longer RFS in biopsies of primary cancers (n = 47, p = 0.011), although the combined marker analysis did not show significant association with OS (Fig. 2b, p = 0.283). In addition, there was a significant association with chemosensitivity (p = 0.004) and FIGO classification (p = 0.029) in primary cancer biopsies (Tables 3 and 4).

In biopsies from carcinoma recurrences, no significant association with RFS could be found (p = 0.121).

Multivariate analysis of synergistic effect
In a multivariate cox regression analysis including age, residual disease, FIGO classification, number of chemotherapy cycles and categorized MPO and IL-17 cell densities, a synergistic effect could be found for MPO+/IL-17+ cases (Table 4).

Table 4: Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in recurrent carcinomas (n = 45)^a

|                | MPO-/IL17- n = 23 (100 %) | MPO+/IL17- n = 4 (100 %) | MPO-/IL17+ n = 12 (100 %) | MPO+/IL17+ n = 6 (100 %) | p-value |
|----------------|---------------------------|---------------------------|---------------------------|---------------------------|---------|
| Age (median, range) | 62 (47–77) | 59.5 (45–69) | 59 (34–68) | 54.5 (39–60) | 0.277   |
| FIGO stage         |              |              |              |              |         |
| II               | 0                         | 0                         | 1 (8.3)                  | 0                         | 0.574   |
| IIIA              | 0                         | 0                         | 1 (8.3)                  | 0                         |         |
| IIIB              | 2 (8.7)                  | 0                         | 2 (16.7)                 | 1 (16.7)                  |         |
| IIIC              | 17 (73.9)               | 4 (100.0)                 | 6 (50.0)                 | 3 (50.0)                  |         |
| IV                | 4 (17.4)                 | 0                         | 2 (16.7)                 | 2 (33.3)                  |         |
| Residual disease  |              |              |              |              |         |
| None             | 7 (30.4)                 | 0                         | 6 (50.0)                 | 2 (33.3)                  | 0.046   |
| <2 cm            | 5 (21.7)                 | 3 (66.7)                  | 5 (41.7)                 | 4 (66.7)                  |         |
| >2 cm            | 10 (43.5)                | 1 (33.3)                  | 1 (8.3)                  | 0                         |         |
| Numbers of chemotherapy cycles |              |              |              |              |         |
| <6               | 3 (13.0)                 | 0                         | 3 (25.0)                 | 1 (16.7)                  | 0.806   |
| 6 or more        | 19 (82.6)                | 4 (100.0)                 | 9 (75.0)                 | 5 (83.3)                  |         |
| CS^b             | 13 (56.5)                | 3 (66.7)                  | 10 (83.3)                | 6 (100.0)                 | 0.123   |
| CR^b             | 10 (43.5)                | 1 (33.3)                  | 2 (16.7)                 | 0                         |         |
| RFS^c (mean/SE)  | 7.7 (1.8)                | 12.5 (7.1)                | 14.2 (2.5)               | 8.3 (2.2)                 | 0.121   |
| OS^c (mean/SE)   | 33.5 (5.8)               | 20 (2.0)                  | 53.4 (9.3)               | 45.2 (6.5)                | 0.074   |

Bold data statistically significant p < 0.05
^a percentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
^b CS chemosensitive, CR chemoresistant
^c RFS recurrence-free survival, OS overall survival
density, the combination of the immune markers was an independent prognostic factor for RFS in primary cancer biopsies (Table 5).

**Discussion**

As in ovarian carcinoma, surgical tumor debulking is often followed by adjuvant platinum-based chemotherapy it would be helpful to find predictive markers for chemoresponse. Based on such biomarkers it would be possible to carry out extended chemotherapy regimen and repetitive surgical procedures. In our previous studies we identified different potential therapeutical targets and IL-17 as predictive marker for chemosensitivity [27, 35–38]. As previously mentioned there is a resurgent interest in the scientific community concerning the role of granulocytes in tumor immunology [22, 24, 31]. Indeed, they have usually been associated with poor prognosis [20]. But experimental models in the past have proposed an anti-tumor role through the activation of T cells [44, 45]. Furthermore recently, granulocyte polarization has been described [22] and the ability of granulocytes to promote lymphocyte activation in the tumor environment has been reported [31].

The composition of tumor microenvironment has been shown to significantly impact tumor progression and clinical outcome [12]. Similar to a variety of cancers of different origins, T lymphocyte infiltration in ovarian cancer has a positive prognostic role [46]. Most interestingly, ovarian cancer infiltration by IL-17 producing cells has been found to be associated with either longer RFS or good prognosis by us and others [27, 47]. However, there is no evidence concerning the potential clinical relevance of granulocyte infiltration in ovarian cancer.

**Table 5** Multivariate Hazard Cox regression analysis of recurrence-free survival considering the categorized combination of both markers

|                          | HR     | 95% CI    | p-values |
|--------------------------|--------|-----------|----------|
| Age                      | 0.99   | 0.96–1.02 | 0.612    |
| MPO + IL17⁻             | 0.64   | 0.17–2.48 | 0.518    |
| MPO-IL17⁺               | 0.26   | 0.10–0.69 | 0.006    |
| MPO + IL17⁺             | 0.23   | 0.07–0.73 | 0.013    |
| Residual disease <2 cm   | 1.03   | 0.48–2.20 | 0.949    |
| Residual disease >2 cm   | 3.93   | 1.47–10.52| 0.007    |
| N of chemotherapy cycles | 1.16   | 0.89–1.52 | 0.276    |
| FIGO IIIA                | 0.08   | 0.00–1.88 | 0.115    |
| FIGO IIIB                | 0.58   | 0.05–6.48 | 0.661    |
| FIGO IIIC                | 0.40   | 0.04–3.61 | 0.413    |
| FIGO IV                  | 0.59   | 0.06–6.00 | 0.652    |

Bold data statistically significant p < 0.05

Multivariate analyses showing Hazard Ratios and p-value for all primary cancer biopsies (n = 46 less than 47 due to missing values) conferred by categorized MPO/IL-17 density, age, residual disease after cytoreductive surgery, number of chemotherapy cycles and FIGO classification.

In our previous study we found that IL-17 positive TICI were significantly more frequent in the chemosensitive ovarian carcinoma group [27]. Granulocytes and other immune cells of the innate immune system can produce IL-17 [28–30]. On the other hand, TNF-alpha in the tumor microenvironment could attract myeloid cells in an IL-17-dependent manner and contribute to tumor-promotion [48]. Therefore we investigated the predictive role of MPO, an enzyme that is expressed in myeloid cells, alone and together with IL-17. Finally we found that the combination of both markers was an independent prognostic factor for RFS. However, in this study IL-17 was the dominant marker for prediction of RFS. A further limitation is the small sample size. Therefore, our results have to be validated in an independent larger patient cohort.

**Conclusion**

Based on the results in this study, we conclude that the combination of high MPO positive cell density and IL-17 expression enhances the indicative value for the response of ovarian carcinomas to chemotherapy, as it in addition has prognostic value regarding recurrence-free survival in ovarian carcinoma. Although, these results have to be validated in a larger cohort.

**Acknowledgments**

The authors acknowledge Serenella Eppenberger-Castori for her advice concerning the statistical analysis.

**Funding**

This study was funded by the Swiss Cancer League (Oncosuisse), grant number OCS 01506-02-2004 for GS.

**Availability of data and materials**

Raw data can be obtained by contacting the corresponding author.

**Authors’ contributions**

RD contributed to the study design and drafted the manuscript. RM performed the IHC evaluation. RD did the statistical analysis and was involved in revising the manuscript. UG and SS collected data and were involved in revising the manuscript. LT, SD, BW, MK and TD contributed to the manuscript content and its revision. GS collected samples and data, contributed to the IHC evaluation and revised the manuscript. All authors read and gave approval to the final manuscript version.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This study was approved by the regional ethics committee of the University Hospital Basel Switzerland. Finally, the study was performed according to the guidelines of the institutional review boards (IRB) of the participating institutions as previously published [35–38]. The need for patient consent for studies using this TMA was originally waived by the ethics committee of northwestern Switzerland (BKNZ). Currently the TMA is handled at the biobank of pathology of the University Hospital Basel.
Author details
1 Department of Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland. 2 Institute for Surgical Research and Hospital Management ICFs, Hebelstrasse 20, 4031 Basel, Switzerland. 3 Department of Gynecology and Obstetrics, Kantonsspital Winterthurer, Brauerstrasse 15, 8403 Winterthur, Switzerland. 4 Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland. 5 Institute of Pathology, Kantonsspital Baden AG, Im Engel 1, 5404 Baden, Switzerland. 6 Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4031 Basel, Switzerland.

Received: 25 January 2016 Accepted: 3 August 2016

Published online: 17 August 2016

References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010; 60:433–4453 (Electronic):277–300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer, 2010; 127(10):2359–2416 (Electronic):2893–2912.
3. Bray F, Loos AH, Tognazzi S, La Vecchia C. Cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2005;113:977–990.
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(10):288–293 (Print):375–385.
5. Stagg J. Mesenchymal stem cells in cancer. Stem Cell Rev. 2008;4:1550–1564 (Print):119–132.
6. Jaspert R, Dunn GP, Lewis JR. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:1424–1434 (Electronic):1630–1640.
7. Oble DA, Loewe R, Yu P, Mihm Jr MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:1424–1434 (Electronic):3.
8. Nosko K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Danooff G, Fuchs CS, Ogino S. Tumor infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222:1096–1096 (Electronic):355–360.
9. Takagi S, Chen K, Schwarz R, Iwasaki S, Hebermann RA, Whiteside TL. Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer. 1989;63:0008–543X (Print):102–119.
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(10),923–203 (Electronic):1690–1692.
11. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010;184(15):560–606 (Electronic):1630–1640.
12. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Immunol. 2010;10:0078–0133 (Electronic):1295–1302.
13. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strier RM, Rosin DL, Okusa MD. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331–42.
14. Lin AM, Rubin CJ, Kandpur R, Wang Y, Ribet M, Yalavarthi S, Villarreal EC, Shah P, Kaplan MJ, Bruce AT. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500.
15. Cui DJ, Tato CM. Immune IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10:0789–89.
16. Erusalimov EB, Bhojanaganwala PS, Quatromoni JG, Stephenson TL, Ranganathan A, Deshpande C, Akimoto T, Vachani A, Listyk L, Hancock WW, Conejo-Garcia JR, Feldman M, Albeida SM, Singhal S. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2011;124:145466–160.
17. Kawaezawa J, Shiono P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1347–1350.
18. Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest. 1993;93:2866–272.
19. Kanayama A, Miyamoto Y. Apoptosis triggered by phagocytosis-related oxidative stress through F Lance prim down-regulation and JNK activation. J Leukoc Biol. 2007;82:1334–42.
20. Stadmöller J, Dimhofer S, Guth U, Thies S, Singer G. ERCC1-immunoeexpression does not predict platinum-resistance in ovarian cancer. Gynecol Oncol. 2008;108:1252–3.
21. Stadmöller J, Guth U, Baumeister D, Moch H, Terracciano L, Singer G. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Oncol. 2007;31:341–4.
22. Stadmöller J, Guth U, Wight E, Kunz-Schughart LA, Hartmann A, Singer G. Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol. 2007;60:307–10.
23. Stadmöller J, Guth U, Reiser U, Diener P-A, Zeimet AG, Wight E, Mirlacher M, Sauter G, Mikhsztch MJ, Singer G. Epithelial growth factor receptor status in primary, and recurrent ovarian cancer. Mod Pathol. 2006;19:0007–010.
24. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih I-M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–8.
25. Singer G, Oldt 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih HM. Mutations in BRF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484–6.
41. Jazaeri AA, Avtrey CS, Chandramouli GVR, Chuang YE, Khan J, Sotiriou C, Aprikova O, Yee CJ, Zorn KK, Birrer MJ, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11:6300–10.

42. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2003;2:1474–1776 (Print):962–72.

43. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60(2001–9746 (Print)):1112–6.

44. Stoppacciaro A, Melani C, Parenta M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med. 1993;178:151–61.

45. Colombo MP, Ferrari G, Stoppacciaro A, Parenta M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173:889–97.

46. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.

47. Kryczek I, Banerjee M, Cheng P, Vatan L, Szelaiga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(1528–0020 (Electronic)):1141–9.

48. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrance T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119:3011–23.